Difference between revisions of "Sutimlimab (Enjaymo)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Jwarner moved page Sutimlimab (BIVV009) to Sutimlimab (Enjaymo): FDA approval)
Line 4: Line 4:
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
*[[Cold agglutinin disease]]
 
*[[Cold agglutinin disease]]
−
#'''CARDINAL:''' Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. [https://doi.org/10.1056/nejmoa2027760 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33826820/ PubMed] NCT03347396
 
−
#'''CADENZA:''' Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022 Sep 1;140(9):980-991. [https://doi.org/10.1182/blood.2021014955 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35687757/ PubMed]
 
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==

Revision as of 10:33, 5 November 2022

Mechanism of action

Anti-C1s antibody

Diseases for which it is used

History of changes in FDA indication

  • 2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)

Also known as

  • Code name: BIVV009
  • Generic name: sutimlimab-jome
  • Brand name: Enjaymo
Retrieved from "https://hemonc.org/w/index.php?title=Sutimlimab_(Enjaymo)&oldid=63788"